MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MTVA MetaVia Inc

Post-Mkt 01-13 16:58:38 EST

7.75

-0.42

-5.11%

盘后7.76

+0.01+0.13%

16:51 EST

High8.10	Low7.08	Vol80.85K
Open8.00	D1 Closing8.17	Amplitude12.49%
Mkt Cap17.90M	Tradable Cap6.46M	Total Shares2.31M
T/O602.75K	T/O Rate9.70%	Tradable Shares833.20K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":7.75,"timestamp":1768338000000,"preClose":8.167,"halted":0,"volume":80849,"hourTrading":{"tag":"盘后","latestPrice":7.76,"preClose":7.75,"latestTime":"16:51 EST","volume":190,"amount":1422.6003,"timestamp":1768341112771},"delay":0,"floatShares":833199,"shares":2309100,"eps":-11.363935,"marketStatus":"Post-Mkt","change":-0.417,"latestTime":"01-13 16:58:38 EST","open":8,"high":8.1,"low":7.08,"amount":602752.74121,"amplitude":0.124893,"askPrice":7.8,"askSize":102,"bidPrice":7.14,"bidSize":39,"shortable":0,"etf":0,"ttmEps":-11.363935,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768352400000},"marketStatusCode":4,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":8.167,"preHourTrading":{"tag":"盘前","latestPrice":7.982,"preClose":8.03,"latestTime":"09:26 EST","volume":53,"amount":453.739996,"timestamp":1768314389988},"postHourTrading":{"tag":"盘后","latestPrice":7.76,"preClose":7.75,"latestTime":"16:51 EST","volume":190,"amount":1422.6003,"timestamp":1768341112771},"volumeRatio":2.611317},"requestUrl":"/m/hq/s/MTVA","defaultTab":"news","newsList":[{"id":"2601812800","title":"MetaVia Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2601812800","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601812800?lang=en_us&edition=fundamental","pubTime":"2026-01-07 02:05","pubTimestamp":1767722700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 13:05 ET (18:05 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2601892160","title":"Metavia Inc. Unveils Pipeline Advancements Targeting Obesity and MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892160","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601892160?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:39","pubTimestamp":1767703199,"startTime":"0","endTime":"0","summary":"Metavia Inc. , a clinical-stage biotechnology company, has released a corporate presentation detailing its focus on developing next-generation therapeutics targeting obesity and metabolic dysfunction-associated steatohepatitis . The presentation outlines the company’s product pipeline, including candidates such as Vanoglipel  and DA-1726, which are being advanced for cardiometabolic diseases. Key risks identified by Metavia include potential impacts from government agency funding, possible Nasdaq delisting, future strategic transactions, and challenges related to clinical trial outcomes and regulatory approvals. The company also highlights factors such as resource allocation, public perception of obesity treatments, and obligations under licensing agreements as potential risks. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL1mJhtR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2601882112","title":"BRIEF-Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss And Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2601882112","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601882112?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:09","pubTimestamp":1767622182,"startTime":"0","endTime":"0","summary":"BRIEF-Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA1CYWC6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2601366884","title":"Metavia Inc. Reports Phase 1b Trial Success for DA-1726 in Obesity and Metabolic Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366884","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366884?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:31","pubTimestamp":1767619883,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL6lbvZs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2601884891","title":"Metavia Inc - 12.3 Mg/Dl Fasted Glucose Reduction by Day 54 in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601884891","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601884891?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:30","pubTimestamp":1767619801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA1CYWC6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2595738124","title":"MetaVia Inc. to Sponsor and Participate in 10th Annual MASH-TAG Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2595738124","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595738124?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:31","pubTimestamp":1767015079,"startTime":"0","endTime":"0","summary":"MetaVia Inc. will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference, taking place January 8-10 at the Chateaux Deer Valley in Park City, Utah. Members of MetaVia's business development and clinical teams are expected to attend the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire  on December 29, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL3zGxTj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2593438924","title":"BRIEF-Metavia Regains Compliance With Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2593438924","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593438924?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:45","pubTimestamp":1766411158,"startTime":"0","endTime":"0","summary":"BRIEF-Metavia Regains Compliance With Nasdaq Minimum Bid Price RequirementDec 22 (Reuters) - MetaVia Inc MTVA.O:METAVIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTSource text: ID:nPn3bl5r6aFurther company coverage: MTVA.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA877HFG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2590231536","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:56 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2590231536","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590231536?lang=en_us&edition=fundamental","pubTime":"2025-12-10 23:56","pubTimestamp":1765382199,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:56 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nAQN2LD12N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2588511057","title":"MetaVia to Implement 1-for-11 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2588511057","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588511057?lang=en_us&edition=fundamental","pubTime":"2025-12-03 00:27","pubTimestamp":1764692878,"startTime":"0","endTime":"0","summary":"MetaVia  said Tuesday it will implement a 1-for-11 reverse stock split of its common stock.The split-adjusted shares will begin trading on the Nasdaq Capital Market on Friday and is intended to comply with Nasdaq's continued listing requirements, the company said.MetaVia said the reverse split will reduce the number of outstanding shares to 2.3 million from about 25.4 million.Shares of MetaVia fell over 17% in recent Tuesday trading.Price: 0.62, Change: -0.13, Percent Change: -17.40","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2588553056","title":"BRIEF-Metavia Inc. Announces 1-For-11 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2588553056","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588553056?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:45","pubTimestamp":1764683129,"startTime":"0","endTime":"0","summary":"BRIEF-Metavia Inc. Announces 1-For-11 Reverse Stock SplitDec 2 (Reuters) - MetaVia Inc MTVA.O:METAVIA INC. ANNOUNCES 1-FOR-11 REVERSE STOCK SPLITSource text: ID:nPn5GjtQcaFurther company coverage: MTVA.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA25X2ZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2586298386","title":"Metavia Inc. Faces Nasdaq Delisting Risk Over $1 Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2586298386","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586298386?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:30","pubTimestamp":1764192656,"startTime":"0","endTime":"0","summary":"Metavia Inc. is currently facing a regulatory issue related to its continued listing on the Nasdaq Capital Market. The company received notice from Nasdaq that it is not in compliance with the minimum bid price requirement, as its stock has traded below $1.00 for 30 consecutive trading days. Metavia has been granted a 180-day extension, until May 26, 2026, to regain compliance, which it plans to address by considering a reverse stock split if necessary. Failure to meet the requirement could result in the company's stock being delisted from Nasdaq.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL11y61P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2581885386","title":"Metavia Reports Positive Phase 2a Results for Vanoglipel in MASH Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2581885386","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581885386?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:31","pubTimestamp":1762522279,"startTime":"0","endTime":"0","summary":"MetaVia Inc. has announced positive new data from its Phase 2a clinical trial evaluating vanoglipel , an oral GPR119 agonist, for the treatment of metabolic dysfunction-associated steatohepatitis . The results, which were presented at the American Association for the Study of Liver Diseases  The Liver Meeting 2025, demonstrated clinically meaningful reductions in HbA1c, improvements in liver inflammation and fibrosis, and favorable changes in plasma lipidomic profiles after 16 weeks of treatment. The data suggest vanoglipel's potential to address both hepatic and metabolic factors in MASH. The findings were shared during a poster presentation on November 10, 2025, and the poster is available on the MetaVia website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL5MWT6x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2581509622","title":"Metavia Inc. Unveils Pipeline Advances Targeting Obesity and MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2581509622","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581509622?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:44","pubTimestamp":1762436691,"startTime":"0","endTime":"0","summary":"Metavia Inc. has presented new clinical data on its pipeline targeting cardiometabolic diseases, including obesity and metabolic dysfunction-associated steatohepatitis . The company highlighted its lead candidate DA-1726, a novel GLP1R/GCGR dual agonist, which demonstrated weight loss of up to 6.3% and reductions in fasted glucose and waist circumference over a 26-33 day period in a Phase 1 study. The candidate was generally well-tolerated, with mild gastrointestinal events reported and no treatment-related discontinuations. Metavia also reported positive Phase 2a top-line data for Vanoglipel  in MASH, confirming primary endpoint achievement and a favorable safety profile. Additional dose-finding and longer-duration studies are ongoing. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL9qfHnV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2581096148","title":"MetaVia Q3 EPS $(0.14) Beats $(0.25) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581096148","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581096148?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:41","pubTimestamp":1762436484,"startTime":"0","endTime":"0","summary":"MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.25) by 43.78 percent. This is a 74.55 percent increase over losses of $(0.55) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48685184/metavia-q3-eps-0-14-beats-0-25-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSYW.SI","TQQQ",".IXIC","PSQ","MTVA","QID","BK4139","USAW.SI","USJW.SI","QLD","SQQQ","NVIW.SI","MNQmain","NQmain"],"gpt_icon":0},{"id":"2581909684","title":"Metavia Inc. reports third quarter 2025 results and updates on clinical programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2581909684","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581909684?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:31","pubTimestamp":1762435912,"startTime":"0","endTime":"0","summary":"Metavia Inc. reported total other income of $0.6 million for the nine months ended September 30, 2025, down from $0.8 million for the same period in 2024, mainly due to $0.3 million in lower interest income, net, and partially offset by a $0.1 million increase in gain from the change in fair value of warrant liabilities. For the third quarter ended September 30, 2025, total other income was $0.1 million, compared to $0.6 million in the third quarter of 2024, reflecting a $0.2 million decrease in interest income and a $0.4 million change in the fair value of warrant liabilities. Cash stood at $14.3 million as of September 30, 2025, compared to $16.0 million as of December 31, 2024, with the company expecting this cash position to fund operations into 2026. During the period, Metavia dosed the first patient in the 8-week 48 mg MAD cohort of its Phase 1 clinical trial for DA-1726 in obesity, with top-line data expected by year-end 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL7tJtJ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2581619807","title":"MetaVia Reports Positive Phase 1 Results for Obesity Drug DA-1726","url":"https://stock-news.laohu8.com/highlight/detail?id=2581619807","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581619807?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:03","pubTimestamp":1762290220,"startTime":"0","endTime":"0","summary":"MetaVia Inc. announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel dual oxyntomodulin analog agonist targeting GLP-1 and glucagon receptors, at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, GA. The Phase 1 study demonstrated favorable safety and tolerability, as well as a pharmacokinetic profile supporting once-weekly dosing. Meaningful reductions in body weight and waist circumference were observed after four weeks of treatment. Additionally, in pre-clinical diet-induced obesity mouse models, DA-1726 achieved comparable weight loss to pemvidutide and showed superior lipid-lowering effects. Results from an extended Phase 1 cohort evaluating a higher 48 mg dose are expected later in 2025. The data have not yet been presented and are scheduled for release at the upcoming conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDLb7lGj7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2580343211","title":"MetaVia Inc  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580343211","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580343211?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:22","pubTimestamp":1762179728,"startTime":"0","endTime":"0","summary":"MetaVia Inc  expected to post a loss of22cents a share - Earnings Preview MetaVia Inc MTVA.OQ MTVA.O is expected to  show no change in quarterly revenue when it reports  results on November 5 (estimat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF1AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2578622384","title":"Metavia Inc. Advances Obesity Treatment with New Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2578622384","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578622384?lang=en_us&edition=fundamental","pubTime":"2025-10-28 02:12","pubTimestamp":1761588732,"startTime":"0","endTime":"0","summary":"Metavia Inc. (($MTVA)) announced an update on their ongoing clinical study. Study Overview: Metavia Inc. (MTVA) has initiated a Phase 1 clinical st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/metavia-inc-advances-obesity-treatment-with-new-clinical-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/metavia-inc-advances-obesity-treatment-with-new-clinical-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2576517338","title":"MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576517338","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576517338?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:31","pubTimestamp":1760963488,"startTime":"0","endTime":"0","summary":"MetaVia Inc., a clinical-stage biotechnology company, announced that two abstracts featuring data on its investigational drug DA-1726 have been accepted for poster presentations at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. DA-1726 is a novel dual oxyntomodulin analog agonist targeting both the glucagon-like peptide-1 receptor  and glucagon receptor . The presentations will include results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of DA-1726, as well as an overview of its potential as a therapy for obesity and related metabolic disorders. Both posters are set to be presented on November 4, 2025. Copies of the posters will be made available on the MetaVia website following the presentations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL8PNqyk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":1},{"id":"2575300218","title":"Metavia Inc. to Present at H.C. Wainwright Liver Disease Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575300218","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575300218?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:31","pubTimestamp":1760445084,"startTime":"0","endTime":"0","summary":"Metavia Inc., a clinical-stage biotechnology company focused on cardiometabolic diseases, will present a company overview at the H.C. Wainwright Liver Disease Virtual Conference on October 21-22, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire  on October 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL4gNq5v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurobopharma.com","stockEarnings":[{"period":"1week","weight":-0.0645},{"period":"1month","weight":-0.1228},{"period":"3month","weight":-0.2721},{"period":"6month","weight":0.1021},{"period":"1year","weight":-0.6396},{"period":"ytd","weight":-0.03}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.067632},{"month":2,"riseRate":0.333333,"avgChangeRate":0.050158},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.011768},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.143887},{"month":5,"riseRate":0.222222,"avgChangeRate":-0.109293},{"month":6,"riseRate":0.555556,"avgChangeRate":0.090563},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.026489},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.189997},{"month":9,"riseRate":0.4,"avgChangeRate":0.065402},{"month":10,"riseRate":0.2,"avgChangeRate":-0.186131},{"month":11,"riseRate":0.3,"avgChangeRate":-0.112358},{"month":12,"riseRate":0.1,"avgChangeRate":-0.160075}],"exchange":"NASDAQ","name":"MetaVia Inc","nameEN":"MetaVia Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MetaVia Inc(MTVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MetaVia Inc,MTVA,MetaVia Inc股票,MetaVia Inc股票老虎,MetaVia Inc股票老虎国际,MetaVia Inc行情,MetaVia Inc股票行情,MetaVia Inc股价,MetaVia Inc股市,MetaVia Inc股票价格,MetaVia Inc股票交易,MetaVia Inc股票购买,MetaVia Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MetaVia Inc(MTVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}